Cargando…

Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials

Objectives: To evaluate the effectiveness and safety of Chinese herbal medicines (CHMs) combined with cyclophosphamide (CTX) for connective tissue disease-associated interstitial lung disease (CTD-ILD) by performing a meta-analysis. Methods: We searched RCTs of Chinese herbal medicines therapy for c...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Xietian, Zhao, Shichao, Xiang, Nan, Chen, Jidong, Xu, Jun, Zhang, Yudan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995361/
https://www.ncbi.nlm.nih.gov/pubmed/36909152
http://dx.doi.org/10.3389/fphar.2023.1064578
_version_ 1784902806296068096
author Yin, Xietian
Zhao, Shichao
Xiang, Nan
Chen, Jidong
Xu, Jun
Zhang, Yudan
author_facet Yin, Xietian
Zhao, Shichao
Xiang, Nan
Chen, Jidong
Xu, Jun
Zhang, Yudan
author_sort Yin, Xietian
collection PubMed
description Objectives: To evaluate the effectiveness and safety of Chinese herbal medicines (CHMs) combined with cyclophosphamide (CTX) for connective tissue disease-associated interstitial lung disease (CTD-ILD) by performing a meta-analysis. Methods: We searched RCTs of Chinese herbal medicines therapy for connective tissue disease-associated interstitial lung disease in ten databases. Methodological quality assessment was performed by the Cochrane collaboration tool. RevMan v5.3 and Stata v14.0 software were used for performing data analysis. This study was conducted and reported following the PRISMA checklist. Results: Overall, seven RCTs with 506 participants were included for this analysis. Current data indicated that Chinese herbal medicines combined with cyclophosphamide contributed to a betterment in improving the clinical efficacy rate of connective tissue disease-associated interstitial lung disease [risk ratio (RR) = 1.21, 95% confidence interval (CI): (1.09, 1.35), p = 0.0003], tended to benefit improvement of lung function, which included VC [weighted mean difference (WMD) = 9.49, 95% CI: (5.54, 13.45), p < 0.00001], FVC [standardized mean difference (SMD) = 0.83, 95% CI: (0.36, 1.29), p = 0.0005], FEV1 [SMD = 0.54, 95% CI: (0.23, 0.86), p = 0.0008], TLC [SMD = 0.90, 95% CI: (0.68, 1.13), p < 0.00001], DLCO [SMD = 1.05, 95% CI: (0.38, 1.73), p = 0.002], and MVV [SMD = 0.83, 95% CI: (0.50, 1.17), p < 0.00001], and it also could significantly reduce the HRCT integral of lungs [SMD = −2.02, 95% CI: (−3.14, −0.91), p = 0.0004] and the level of ESR [WMD = −13.33, 95% CI: (−18.58, −8.09), p < 0.00001]. Furthermore, there was no statistical significance in the incidence of adverse events (AEs), which indicate that Chinese herbal medicines combined with cyclophosphamide is safe and does not increase adverse events compared with cyclophosphamide alone. Conclusion: Our analysis indicates that Chinese herbal medicines combined with cyclophosphamide may be a more effective strategy on the treatment of connective tissue disease-associated interstitial lung disease in the clinic. Because it included studies with relatively small sample size, the results need to be confirmed by more well-designed and large-scale RCTs. Systematic Review Registration: https://10.37766/inplasy2022.12.0010.
format Online
Article
Text
id pubmed-9995361
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99953612023-03-10 Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials Yin, Xietian Zhao, Shichao Xiang, Nan Chen, Jidong Xu, Jun Zhang, Yudan Front Pharmacol Pharmacology Objectives: To evaluate the effectiveness and safety of Chinese herbal medicines (CHMs) combined with cyclophosphamide (CTX) for connective tissue disease-associated interstitial lung disease (CTD-ILD) by performing a meta-analysis. Methods: We searched RCTs of Chinese herbal medicines therapy for connective tissue disease-associated interstitial lung disease in ten databases. Methodological quality assessment was performed by the Cochrane collaboration tool. RevMan v5.3 and Stata v14.0 software were used for performing data analysis. This study was conducted and reported following the PRISMA checklist. Results: Overall, seven RCTs with 506 participants were included for this analysis. Current data indicated that Chinese herbal medicines combined with cyclophosphamide contributed to a betterment in improving the clinical efficacy rate of connective tissue disease-associated interstitial lung disease [risk ratio (RR) = 1.21, 95% confidence interval (CI): (1.09, 1.35), p = 0.0003], tended to benefit improvement of lung function, which included VC [weighted mean difference (WMD) = 9.49, 95% CI: (5.54, 13.45), p < 0.00001], FVC [standardized mean difference (SMD) = 0.83, 95% CI: (0.36, 1.29), p = 0.0005], FEV1 [SMD = 0.54, 95% CI: (0.23, 0.86), p = 0.0008], TLC [SMD = 0.90, 95% CI: (0.68, 1.13), p < 0.00001], DLCO [SMD = 1.05, 95% CI: (0.38, 1.73), p = 0.002], and MVV [SMD = 0.83, 95% CI: (0.50, 1.17), p < 0.00001], and it also could significantly reduce the HRCT integral of lungs [SMD = −2.02, 95% CI: (−3.14, −0.91), p = 0.0004] and the level of ESR [WMD = −13.33, 95% CI: (−18.58, −8.09), p < 0.00001]. Furthermore, there was no statistical significance in the incidence of adverse events (AEs), which indicate that Chinese herbal medicines combined with cyclophosphamide is safe and does not increase adverse events compared with cyclophosphamide alone. Conclusion: Our analysis indicates that Chinese herbal medicines combined with cyclophosphamide may be a more effective strategy on the treatment of connective tissue disease-associated interstitial lung disease in the clinic. Because it included studies with relatively small sample size, the results need to be confirmed by more well-designed and large-scale RCTs. Systematic Review Registration: https://10.37766/inplasy2022.12.0010. Frontiers Media S.A. 2023-02-23 /pmc/articles/PMC9995361/ /pubmed/36909152 http://dx.doi.org/10.3389/fphar.2023.1064578 Text en Copyright © 2023 Yin, Zhao, Xiang, Chen, Xu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yin, Xietian
Zhao, Shichao
Xiang, Nan
Chen, Jidong
Xu, Jun
Zhang, Yudan
Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title_full Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title_fullStr Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title_full_unstemmed Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title_short Efficacy and safety of Chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: A meta-analysis of randomized controlled trials
title_sort efficacy and safety of chinese herbal medicines combined with cyclophosphamide for connective tissue disease-associated interstitial lung disease: a meta-analysis of randomized controlled trials
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995361/
https://www.ncbi.nlm.nih.gov/pubmed/36909152
http://dx.doi.org/10.3389/fphar.2023.1064578
work_keys_str_mv AT yinxietian efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials
AT zhaoshichao efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials
AT xiangnan efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials
AT chenjidong efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials
AT xujun efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials
AT zhangyudan efficacyandsafetyofchineseherbalmedicinescombinedwithcyclophosphamideforconnectivetissuediseaseassociatedinterstitiallungdiseaseametaanalysisofrandomizedcontrolledtrials